Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Abstract LB-B13: Lurbinectedin down-regulates ASCL1 transcription factor in Small Cell Lung Cancer (SCLC)

Laura Mannarino, Ilaria Craparotta, Federica Mirimao, Nicolò Panini, Monica Lupi, Giulia Protti, Roberta Frapolli, Sergio Marchini, Maurizio D'Incalci

Mol Cancer Ther (2019) 18 (12_Supplement): LB-B13.

https://doi.org/10.1158/1535-7163.TARG-19-LB-B13

Published: 01 December 2019

View articletitled, Abstract LB-B13: Lurbinectedin down-regulates ASCL1 transcription factor in Small Cell Lung Cancer (SCLC)

Journal Articles

Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response

Marta Cesca, Lavinia Morosi, Alexander Berndt, Ilaria Fuso Nerini, Roberta Frapolli, Petra Richter, Alessandra Decio, Olaf Dirsch, Edoardo Micotti, Silvia Giordano, Maurizio D'Incalci, Enrico Davoli, Massimo Zucchetti, Raffaella Giavazzi

Mol Cancer Ther (2016) 15 (1): 125–135.

https://doi.org/10.1158/1535-7163.MCT-15-0063

Published: 07 January 2016

View articletitled, Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response

Includes: Supplementary data

Journal Articles

Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer

Manuela Porru, Simona Artuso, Erica Salvati, Armandodoriano Bianco, Marco Franceschin, Maria Grazia Diodoro, Daniela Passeri, Augusto Orlandi, Francesco Savorani, Maurizio D'Incalci, Annamaria Biroccio, Carlo Leonetti

Mol Cancer Ther (2015) 14 (11): 2541–2551.

https://doi.org/10.1158/1535-7163.MCT-15-0253

Published: 03 November 2015

View articletitled, Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer

Includes: Supplementary data

Journal Articles

Abstract C93: Collateral sensitivity to cisplatin of trabectedin-resistant cell lines.

Maurizio D'Incalci, Benedetta Colmegna, Sarah Uboldi, Roberta Frapolli, Simonetta Andrea Licandro, Eugenio Erba, Carlos M. Galmarini, Nadia Badri

Mol Cancer Ther (2013) 12 (11_Supplement): C93.

https://doi.org/10.1158/1535-7163.TARG-13-C93

Published: 01 November 2013

View articletitled, Abstract C93: Collateral sensitivity to cisplatin of trabectedin-resistant cell lines.

Journal Articles

Abstract C161: Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors.

Ramiro Vázquez, Lucil Astorgues-Xerri, Esteban Cvitkovic, Mohamed Bekradda, Roman Fleck, Julie Gormley, Richard Buick, Paul Kerr, Eric Raymond, Maurizio D'Incalci, Roberta Frapolli, María Eugenia Riveiro

Mol Cancer Ther (2013) 12 (11_Supplement): C161.

https://doi.org/10.1158/1535-7163.TARG-13-C161

Published: 01 November 2013

View articletitled, Abstract C161: Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors.

Journal Articles

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

Ezia Bello, Giulia Taraboletti, Gennaro Colella, Massimo Zucchetti, Daniele Forestieri, Simonetta A. Licandro, Alexander Berndt, Petra Richter, Maurizio D'Incalci, Ennio Cavalletti, Raffaella Giavazzi, Gabriella Camboni, Giovanna Damia

Mol Cancer Ther (2013) 12 (2): 131–140.

https://doi.org/10.1158/1535-7163.MCT-12-0275-T

Published: 10 February 2013

View articletitled, The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

Includes: Supplementary data

Journal Articles

Abstract A17: Mode of action of trabectedin in myxoid liposarcomas.

Silvana Di Giandomenico, Roberta Frapolli, Ezia Bello, Silvana Pilotti, Paolo Casali, Federica Grosso, Roberta Sanfilippo, Alessandro Gronchi, Carlos Galmarini, Maurizio D'Incalci

Mol Cancer Ther (2011) 10 (11_Supplement): A17.

https://doi.org/10.1158/1535-7163.TARG-11-A17

Published: 12 November 2011

View articletitled, Abstract A17: Mode of action of trabectedin in myxoid liposarcomas.

Journal Articles

Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells

Katherine S. Lovejoy, Maria Serova, Ivan Bieche, Shahin Emami, Maurizio D'Incalci, Massimo Broggini, Eugenio Erba, Christian Gespach, Esteban Cvitkovic, Sandrine Faivre, Eric Raymond, Stephen J. Lippard

Mol Cancer Ther (2011) 10 (9): 1709–1719.

https://doi.org/10.1158/1535-7163.MCT-11-0250

Published: 07 September 2011

View articletitled, Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells

Includes: Supplementary data

Journal Articles

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

Maurizio D'Incalci, Carlos M. Galmarini

Mol Cancer Ther (2010) 9 (8): 2157–2163.

https://doi.org/10.1158/1535-7163.MCT-10-0263

Published: 09 August 2010

View articletitled, A Review of Trabectedin (ET-743): A Unique Mechanism of Action

Journal Articles

Abstract B64: Gene expression profile of a liposarcoma mixoid cell line selected in vitro for resistance to Trabectedin

Sergio M. Marchini, Sergio Bernasconi, Eugenio Erba, Sarah Uboldi, Luca Clivio, Giovanna Chiorino, Annapaola Santarsier, Ilara Fuso, Elena Marangon, Federica Sala, Carlos Galmarini, Juan Carlos Tercero, Roberto Mantovani, Maurizio D'Incalci

Mol Cancer Ther (2009) 8 (12_Supplement): B64.

https://doi.org/10.1158/1535-7163.TARG-09-B64

Published: 10 December 2009

View articletitled, Abstract B64: Gene expression profile of a liposarcoma mixoid cell line selected in vitro for resistance to Trabectedin

Journal Articles

Abstract B198: The pattern of in vivo biological activity of Zalypsis® is different from that of trabectedin

Roberta Frapolli, E. Bello, Carlos Galmarini, Carmen Cuevas, Pablo M. Aviles, Maria José Guillen, Maurizio D'Incalci

Mol Cancer Ther (2009) 8 (12_Supplement): B198.

https://doi.org/10.1158/1535-7163.TARG-09-B198

Published: 10 December 2009

View articletitled, Abstract B198: The pattern of in vivo biological activity of Zalypsis® is different from that of trabectedin

Journal Articles

Abstract C170: Inhibition of poly(ADP‐ribose) polymerase (PARP) increases the therapeutic efficacy of the G‐quadruplex ligand RHPS4/irinotecan combination in cancer xenografts

Carlo Leonetti, Erica Salvati, Angela Rizzo, Marco Scarsella, Lucio Tentori, Grazia Graziani, Maurizio D'Incalci, Malcolm FG Stevens, Augusto Orlandi, Daniela Passeri, Gabriella Zupi, Annamaria Biroccio

Mol Cancer Ther (2009) 8 (12_Supplement): C170.

https://doi.org/10.1158/1535-7163.TARG-09-C170

Published: 10 December 2009

View articletitled, Abstract C170: Inhibition of poly(ADP‐ribose) polymerase (PARP) increases the therapeutic efficacy of the G‐quadruplex ligand RHPS4/irinotecan combination in cancer xenografts

Journal Articles

Abstract A257: Antitumor activity of E‐3810, a new, potent and selective dual inhibitor of VEGF and FGF receptors

Giovanna Damia, Ezia Bello, Gennaro Colella, Valentina Scarlato, Raffaella Giavazzi, Maurizio D'Incalci, Roberta Cereda, Ennio Cavalletti, Silvano Spinelli, Gabriella Camboni

Mol Cancer Ther (2009) 8 (12_Supplement): A257.

https://doi.org/10.1158/1535-7163.TARG-09-A257

Published: 10 December 2009

View articletitled, Abstract A257: Antitumor activity of E‐3810, a new, potent and selective dual inhibitor of VEGF and FGF receptors

Journal Articles

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

Claudia Forni, Mario Minuzzo, Emanuela Virdis, Elena Tamborini, Matteo Simone, Michele Tavecchio, Eugenio Erba, Federica Grosso, Alessandro Gronchi, Pierre Aman, Paolo Casali, Maurizio D'Incalci, Silvana Pilotti, Roberto Mantovani

Mol Cancer Ther (2009) 8 (2): 449–457.

https://doi.org/10.1158/1535-7163.MCT-08-0848

Published: 11 February 2009

View articletitled, Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

Includes: Supplementary data

Journal Articles

Pharmacokinetic of the novel oral camptothecin Gimatecan in patients with advanced or metastatic soft tissue sarcoma

Massimo Zucchetti, Roberta Frapolli, Filippo Saracino, Silvia Pace, Paola Barbieri, Susan McCanna, Federica Grosso, Jean Blay, Peter Reichardt, Maurizio D'Incalci

Mol Cancer Ther (2007) 6 (11_Supplement): C153.

Published: 01 November 2007

View articletitled, Pharmacokinetic of the novel oral camptothecin Gimatecan in patients with advanced or metastatic soft tissue sarcoma

Journal Articles

RHPS4 telomere-interactive molecule: an active antitumoral agent with a high therapeutic index and a favorable integration with camptothecin in preclinical models of solid tumors

Carlo Leonetti, Marco Scarsella, Angela Rizzo, Erica Salvati, Maurizio D'Incalci, Malcolm Stevens, Antonella Stoppacciaro, Antonella Stoppacciaro, Eric Gilson, Gabriella Zupi, Annamaria Biroccio

Mol Cancer Ther (2007) 6 (11_Supplement): A279.

Published: 01 November 2007

View articletitled, RHPS4 telomere-interactive molecule: an active antitumoral agent with a high therapeutic index and a favorable integration with camptothecin in preclinical models of solid tumors

Journal Articles

Novel camptothecin ST1968 is very active in pediatric tumors xenografts models with negligible toxicity as compared to Irinotecan

Daniela Meco, Angela Maria Di Francesco, Tiziana Servidei, Anna Rita Torella, Gabriella Cusano, Maurizio D'Incalci, Claudio Pisano, Riccardo Riccardi

Mol Cancer Ther (2007) 6 (11_Supplement): C7.

Published: 01 November 2007

View articletitled, Novel camptothecin ST1968 is very active in pediatric tumors xenografts models with negligible toxicity as compared to Irinotecan

Journal Articles

IDN 6140: A new taxane derivative exhibiting a different and favorable pharmacokinetic profile from paclitaxel.

Elena Marangon, Federica Sala, Roberta Frapolli, Carla Manzotti, Paolo Morazzoni, Stella Tinelli, Cristiano Ferlini, Maurizio D'Incalci, Massimo Zucchetti

Mol Cancer Ther (2007) 6 (11_Supplement): C146.

Published: 01 November 2007

View articletitled, IDN 6140: A new taxane derivative exhibiting a different and favorable pharmacokinetic profile from paclitaxel.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract LB-B13: Lurbinectedin down-regulates ASCL1 transcription factor in Small Cell Lung Cancer (SCLC)

Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response

Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer

Abstract C93: Collateral sensitivity to cisplatin of trabectedin-resistant cell lines.

Abstract C161: Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors.

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

Abstract A17: Mode of action of trabectedin in myxoid liposarcomas.

Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

Abstract B64: Gene expression profile of a liposarcoma mixoid cell line selected in vitro for resistance to Trabectedin

Abstract B198: The pattern of in vivo biological activity of Zalypsis® is different from that of trabectedin

Abstract C170: Inhibition of poly(ADP‐ribose) polymerase (PARP) increases the therapeutic efficacy of the G‐quadruplex ligand RHPS4/irinotecan combination in cancer xenografts

Abstract A257: Antitumor activity of E‐3810, a new, potent and selective dual inhibitor of VEGF and FGF receptors

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

Pharmacokinetic of the novel oral camptothecin Gimatecan in patients with advanced or metastatic soft tissue sarcoma

RHPS4 telomere-interactive molecule: an active antitumoral agent with a high therapeutic index and a favorable integration with camptothecin in preclinical models of solid tumors

Novel camptothecin ST1968 is very active in pediatric tumors xenografts models with negligible toxicity as compared to Irinotecan

IDN 6140: A new taxane derivative exhibiting a different and favorable pharmacokinetic profile from paclitaxel.

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only